Increased DNA synthesis and repair-enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustards. 1991

R Geleziunas, and A McQuillan, and A Malapetsa, and M Hutchinson, and D Kopriva, and M A Wainberg, and J Hiscott, and J Bramson, and L Panasci
Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada.

Resistance to the nitrogen mustards in patients with chronic lymphocytic leukemia (CLL) correlates with an enhanced removal of melphalan-induced DNA interstrand cross-links. This finding suggests that DNA repair enzymes may be involved in this process. The activity of 3-methyladenine-DNA glycosylase, which can release altered bases, including adducts at the N-7 position of guanine, was increased significantly in lymphocytes from patients with resistant CLL compared with those from untreated CLL patients. Since glycosylase activity varies with cell proliferation, the amount of [3H]thymidine incorporated into DNA was determined and found to be elevated almost threefold in lymphocytes from patients with resistant CLL. The ratio of glycosylase activity to level of thymidine incorporation did not differ between these two groups of patients. Northern blot analysis of ERCC1 gene (a putative DNA repair enzyme involved in nucleotide excision repair) expression in lymphocytes from patients with CLL revealed multiple gene transcripts (1.1, 3.4, and 3.8 kilobases). In addition, analysis of two samples revealed the presence of a 2.6-kilobase transcript. The 2.6-kilobase transcript was recognized by specific RNA probes that hybridize to antisense ERCC1 transcripts. Levels of expression of the 1.1-kilobase protein encoding transcript in lymphocytes from patients with resistant CLL were increased twofold to threefold above those of untreated patients with CLL. These results indicate that increased expression of ERCC1 and increased activity of 3-methyladenine-DNA glycosylase occur with the development of resistance to the nitrogen mustards in patients with CLL, suggesting a role for enhanced DNA repair in this process.

UI MeSH Term Description Entries
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008297 Male Males
D008558 Melphalan An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen. Medphalan,Merphalan,Phenylalanine Mustard,Sarcolysine,Sarkolysin,4-(Bis(2-chloroethyl)amino)phenylalanine,Alkeran,L-PAM,Mustard, Phenylalanine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009588 Nitrogen Mustard Compounds A group of alkylating agents derived from mustard gas, with the sulfur replaced by nitrogen. They were formerly used as toxicants and vesicants, but now function as antineoplastic agents. These compounds are also powerful mutagens, teratogens, immunosuppressants, and carcinogens. Compounds, Nitrogen Mustard,Mustard Compounds, Nitrogen
D009699 N-Glycosyl Hydrolases A class of enzymes involved in the hydrolysis of the N-glycosidic bond of nitrogen-linked sugars. Glycoside Hydrolases, Nitrogen-linked,Hydrolases, N-Glycosyl,Nucleosidase,Nucleosidases,Nucleoside Hydrolase,Nitrogen-linked Glycoside Hydrolases,Nucleoside Hydrolases,Glycoside Hydrolases, Nitrogen linked,Hydrolase, Nucleoside,Hydrolases, N Glycosyl,Hydrolases, Nitrogen-linked Glycoside,Hydrolases, Nucleoside,N Glycosyl Hydrolases,Nitrogen linked Glycoside Hydrolases
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004260 DNA Repair The removal of DNA LESIONS and/or restoration of intact DNA strands without BASE PAIR MISMATCHES, intrastrand or interstrand crosslinks, or discontinuities in the DNA sugar-phosphate backbones. DNA Damage Response
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug

Related Publications

R Geleziunas, and A McQuillan, and A Malapetsa, and M Hutchinson, and D Kopriva, and M A Wainberg, and J Hiscott, and J Bramson, and L Panasci
October 1998, Blood,
R Geleziunas, and A McQuillan, and A Malapetsa, and M Hutchinson, and D Kopriva, and M A Wainberg, and J Hiscott, and J Bramson, and L Panasci
April 1995, Cancer letters,
R Geleziunas, and A McQuillan, and A Malapetsa, and M Hutchinson, and D Kopriva, and M A Wainberg, and J Hiscott, and J Bramson, and L Panasci
July 1977, Cancer letters,
R Geleziunas, and A McQuillan, and A Malapetsa, and M Hutchinson, and D Kopriva, and M A Wainberg, and J Hiscott, and J Bramson, and L Panasci
September 1977, European journal of cancer,
R Geleziunas, and A McQuillan, and A Malapetsa, and M Hutchinson, and D Kopriva, and M A Wainberg, and J Hiscott, and J Bramson, and L Panasci
September 1989, Biochemical pharmacology,
R Geleziunas, and A McQuillan, and A Malapetsa, and M Hutchinson, and D Kopriva, and M A Wainberg, and J Hiscott, and J Bramson, and L Panasci
November 1994, American journal of hematology,
R Geleziunas, and A McQuillan, and A Malapetsa, and M Hutchinson, and D Kopriva, and M A Wainberg, and J Hiscott, and J Bramson, and L Panasci
March 1970, Cancer research,
R Geleziunas, and A McQuillan, and A Malapetsa, and M Hutchinson, and D Kopriva, and M A Wainberg, and J Hiscott, and J Bramson, and L Panasci
April 1988, Cancer research,
R Geleziunas, and A McQuillan, and A Malapetsa, and M Hutchinson, and D Kopriva, and M A Wainberg, and J Hiscott, and J Bramson, and L Panasci
November 1983, Cancer research,
R Geleziunas, and A McQuillan, and A Malapetsa, and M Hutchinson, and D Kopriva, and M A Wainberg, and J Hiscott, and J Bramson, and L Panasci
January 2002, Leukemia,
Copied contents to your clipboard!